Navigation Links
Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis
Date:3/13/2008

ECUBLENS, SWITZERLAND, March 13 /PRNewswire-FirstCall/ - Neurochem (International) Limited (Neurochem), a wholly-owned subsidiary of Neurochem Inc. (NASDAQ: NRMX; TSX: NRM), announces that the Company is taking new initiatives to pursue the drug development program for its investigational product candidate, eprodisate (KIACTA(TM)), to obtain market approval for the treatment of Amyloid A (AA) amyloidosis. Neurochem's decision to build upon its eprodisate (KIACTA(TM)) asset and take steps to initiate a second Phase III clinical trial is based principally on the fact that AA amyloidosis is a life-threatening disease for which there is no specific treatment, on the data obtained from the first Phase II/III clinical trial, which yielded promising efficacy results on the study endpoints, on the benign safety profile of eprodisate (KIACTA(TM)) in patients diagnosed with AA amyloidosis, and on its discussions with the regulatory agencies and related scientific advisory committees. As part of the approval process for the investigational product candidate, both the regulatory agencies in the United States and in the European Union recommended an additional confirmatory efficacy Phase III clinical trial, which will have a target significance level (p-value) of 0.05 rather than the p-value of 0.01, which had been required for an approval based on a single efficacy study. Based on these recommendations, the Company will enter into discussions with the U.S. Food and Drug Administration (FDA) and with the European Medicines Agency (EMEA) to reach agreement on the terms for an approval of eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis. As part of this strategic decision, the Company is also announcing that it is withdrawing its current mark
'/>"/>

SOURCE NEUROCHEM INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Neurochem reports results for third quarter of fiscal 2007
2. Neurochem announces departure of Dr. Philippe Calais, President, Global Business
3. Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review
4. Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis
5. Neurochem to present at JPMorgan Healthcare Conference
6. Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business
7. Neurochem to present at 2008 BIO CEO & Investor Conference - Presentation will be Web cast live
8. Neurochem reports results for fourth quarter and fiscal year 2007 and important advances on corporate objectives
9. Neurochem announces departure of two members of management team
10. DSS Research Moves Corporate Office
11. Sutter Moves to Reduce Public Accountability, Slash Hospital Beds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2015)... 24, 2015 Women’s Excellence ... pressure measurements in patients’ bladder and urethra. This provides ... it if they have reported symptoms of stress urinary ... Women’s Excellence in Bladder Control is a comprehensive center ... or problems with overall control of their bladder. The ...
(Date:5/24/2015)... 2015 The federal court overseeing ... has scheduled its next monthly Case Management Conference ... According to court documents filed in the U.S. ... will be convened on June 2, 2015, at ... Liability Litigation - MDL No. 2545) , “Our ...
(Date:5/24/2015)... Arizona (PRWEB) May 24, 2015 ... former Millennial Media strategy executive Jay Krihak as ... Medicx looks to ramp up its expertise and ... of the Pharmaceutical and Health sectors. , Krihak ... tech executive. Most recently, Krihak led sales planning ...
(Date:5/23/2015)... City, FL (PRWEB) May 23, 2015 On ... to build a new playground for Branches Florida City exactly ... the former play space in 2010. , A large fire ... new playground on May 23, 2010 in the middle of ... watched. The fire was later declared arson even though it ...
(Date:5/23/2015)... (PRWEB) May 23, 2015 With the ... businesses, are finding it increasingly difficult to provide their ... fail to provide adequate insurance for employees stand to ... been such an integral part of a business’s success ... healthcare for businesses, Online USA Doctors has created a ...
Breaking Medicine News(10 mins):Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 3Health News:Medicx Media Solutions Expands Executive Team 2Health News:Five Years After Fire, Branches Rebuilds Playground 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3
... treatment has been effective for inoperable liver cancer. It is a year ... showing a 25 ... success rate in either reducing tumour size or the number of tumours. ... liver tumours, who cannot be treated by any other means. ...
... to babies with low birth weight can significantly improve ... from infectious diseases. The research involved 1,154 full-term but ... most weighing 5 1/2 pounds or less. Mothers fed ... Fifteen of the 20 who died had not been ...
... breakfast and a steaming cup of tea may increase a woman's ... food each morning are at twice the risk of the most ... the incidence of cancer is to begin the day with a ... the oesophagus - the food pipe connecting the stomach with the ...
... help explain why obese people who carry most of their ... of heart disease and other health problems. The findings may ... // ,It is no news that obesity increases ... diabetes, but where these extra pounds accumulate on the body ...
... stimulants like Ritalin are not at risk for cocaine ... that stimulant treatment in childhood may blunt the pleasurable ... children and teens with ADHD are treated with stimulant ... focus patients' attention and calm behavior. But there remain ...
... to suffer brain cell damage from long-term use of the ... if they stop taking the drug. Studies have shown that ... damage nerve endings that release serotonin, a brain chemical that ... to damage brain cells that transmit nerve signals. // ...
Cached Medicine News:Health News:Cut down on fries 2
(Date:5/22/2015)... , May 22, 2015  The U.S. ... Zarxio (filgrastim-sndz) -- the first biosimilar product approved ... -- points toward growth in the contract manufacturing ... mainstream CMO industry is geared to the production ... produce major biopharmaceutical products. The healthcare market research ...
(Date:5/22/2015)... 2015 Research and Markets( http://www.researchandmarkets.com/research/28m7nx/guide_to_prepare ) ... to Prepare Application Dossiers for Oversea Medical device ... report to their offering. The ... market of the most growth potentiality, which is ... and producers to penetrate such market. It is ...
(Date:5/22/2015)... 22, 2015 Richmond Pharmacology ... unit with a worldwide reputation for excellence in ... publications in peer reviewed medical journals. Its officers ... regulators in discussions about rules for transparency and ... (Logo: http://photos.prnewswire.com/prnh/20150522/745125) , Clinical research is ...
Breaking Medicine Technology:Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 2China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 3
... United Seating & Mobility (USM) is excited to ... Kentucky Mobility (CKM) to acquire and merge its complex mobility ... as well as central, eastern and southern Kentucky. ... position within a core market for us and supports our ...
... 22, 2011 The structure of a biopharmaceutical ... the changing goals and strategies. Realigning to support ... reflect priorities and resources are key improvement areas ... "Differentiated services hold great value during times of ...
Cached Medicine Technology:Pharmaceutical Internal Communications Function Morphs to Address Corporate Priorities 2
Aspirating adjustable lid speculum is ideal for cataract and laser refractive procedures....
Open 11 mm blades. Dull finish. Most popular size or model....
Adjustable lid speculum with mm blades. Miniature frame ideal for deep set eyes and small orbital structures....
Solid 4 mm blades. Locking thumb. Dull finish. Holes in bar decrease weight of speculum....
Medicine Products: